Patient and Caregivers’ Perspectives on Biosimilar Use in Pediatric Inflammatory Bowel Disease

Yossef, Lina; Wright, Molly; Benedict, Jason; Morris, Grant; McNicol, Megan; Boyle, Brendan; Dotson, Jennifer L.; Michel, H; Maltz, Ross

doi:10.1097/mpg.0000000000003462

Cited by 3 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the lower expense and similar safety and efficacy biosimilars offer, biosimilars have continued to be underutilized in practice (18,30,31). The underutilization of biosimilars could be due to the lack of provider, patient, and caregiver comfort levels with biosimilars (18,30–33). This study adds to the growing literature supporting similar outcomes of infliximab biosimilars compared to the infliximab originator in pediatric patients with IBD (17,18,20).…”

Section: Discussionmentioning

confidence: 99%

Similar Growth Outcomes in Children with Inflammatory Bowel Disease Initiated on Infliximab Originator or Biosimilar

McClinchie

Lakhani

Abdel‐Rasoul

et al. 2023

Journal of Pediatric Gastroenterology &Amp; Nutrition

Self Cite

View full text Add to dashboard Cite

Background: Growth is an important clinical outcome, especially in childhood-onset inflammatory bowel disease (IBD). Prior research has demonstrated growth improvements with infliximab therapy. There are limited studies evaluating whether clinical and growth outcomes in children initiated on the infliximab originator and infliximab biosimilar are similar. Methods: This was a single-center retrospective review of patients with IBD, younger than 17 years old, and initiated on the infliximab originator or biosimilar for at least 12 months between April 2016 and February 2021. Propensity score matching was utilized. Laboratory values, disease activity scores, and growth values were collected at baseline (prior to infliximab initiation), 6 months and 12 months post initiation. Linear mixed models with random intercepts were used to test differences in measures over time and between study groups. Results: There were 113 patients on the originator and 39 patients on a biosimilar who met eligibility criteria. Propensity score methodology identified 37 dyads (1:1 match). Weight, height, and body mass index z-scores increased over time (from baseline to 12 months) for both groups (p<0.05) and there was a similar rate of change between study groups. Clinical outcomes of lab values (albumin, c-reactive protein, and hemoglobin) and disease activity scoring were similar from baseline to 12 months between study groups. Conclusions: There were similar improvements in growth and clinical outcomes in patients initiated on the infliximab originator compared to an infliximab biosimilar agent. This study adds to the limited research evaluating whether infliximab biosimilars have similar growth outcomes in children with IBD.

show abstract

Section: Discussionmentioning

confidence: 99%

Similar Growth Outcomes in Children with Inflammatory Bowel Disease Initiated on Infliximab Originator or Biosimilar

McClinchie

Lakhani

Abdel‐Rasoul

et al. 2023

Journal of Pediatric Gastroenterology &Amp; Nutrition

Self Cite

View full text Add to dashboard Cite

show abstract

Patients’ Perceptions of Biosimilars: A Systematic Review

Wu,

Wang,

Wang

et al. 2023

BioDrugs

View full text Add to dashboard Cite

Barriers and Enablers Affecting the Uptake of Biosimilar Medicines Viewed Through the Lens of Actor Network Theory: A Systematic Review

Rieger,

Dean,

Hall

et al. 2024

BioDrugs

View full text Add to dashboard Cite

Background and Objective Biosimilars represent an opportunity to realise savings against the costs of innovative medicines. Despite efforts made by stakeholders, there are numerous barriers to the uptake of biosimilars. To realise the promise of biosimilars reducing costs, barriers must be identified, understood, and overcome, and enablers magnified. The aim of this systematic review is to summarise the enablers and barriers affecting uptake of biosimilars through the application of a classification system to organise them into healthcare professional (HCP), patient, or systemic categories. Methods A s ystematic literature search was performed in PubMed, Scopus, CINAHL, eConlit, and Embase. Included were primary research studies published in English between Jan 2017 through June 2023 focused on enablers and barriers affecting uptake of biosimilars. Excluded studies comprised comparisons of biosimilar efficacy and safety versus the reference biologic. One reviewer extracted data that included classification of barriers or enablers, the sub-classification, and the identification of the degree of agency associated with the actor through their role and associations as a mediator within their network, through the application of Actor Network Theory. The data were validated by a second reviewer (PV). Results Of the 94 studies included, 59 were cross-sectional, 20 were qualitative research, 12 were cohort studies, and three were economic evaluations. Within the review, 51 of the studies included HCP populations and 35 included patients. Policies and guidelines were the most cited group of enablers, overall. Systemic enablers were addressed in 29 studies. For patients, the most frequently cited enabler was positive framing of a biosimilar, while for HCPs, cost benefit was the most frequently noted enabler. The most frequently discussed systemic barrier to biosimilar acceptance was lack of effective policies or guidelines, followed by lack of financial incentives, while the most significant barriers for HCPs and patients, respectively, were their lack of general knowledge about biosimilars and concerns about safety and efficacy. Systemic actors and HCPs most frequently acted with broad degree of agency as mediators, while patient most frequently acted with a narrow degree of agency as mediators within their networks. Conclusions Barriers and enablers affecting uptake of biosimilars are interconnected within networks, and can be divided into systemic, HCP, and patient categories. Understanding the agency of actors within networks may allow for more comprehensive and effective approaches. Systemic enablers in the form of policies appear to be the most effective overall levers in affecting uptake of biosimilars, with policy makers advised to give careful consideration to appropriately educating HCPs and positively framing biosimilars for patients. Supplementary Information ...

show abstract

Patient and Caregivers’ Perspectives on Biosimilar Use in Pediatric Inflammatory Bowel Disease

Cited by 3 publications

References 32 publications

Similar Growth Outcomes in Children with Inflammatory Bowel Disease Initiated on Infliximab Originator or Biosimilar

Similar Growth Outcomes in Children with Inflammatory Bowel Disease Initiated on Infliximab Originator or Biosimilar

Patients’ Perceptions of Biosimilars: A Systematic Review

Barriers and Enablers Affecting the Uptake of Biosimilar Medicines Viewed Through the Lens of Actor Network Theory: A Systematic Review

Contact Info

Product

Resources

About